Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography

Alexander Sparreboom(Slotervaartziekenhuis), Jos H. Beijnen(The Netherlands Cancer Institute), Willem J. Noojien(The Netherlands Cancer Institute), Olaf van Tellingen(Dutch Cancer Society)
Journal of Chromatography B Biomedical Sciences and Applications
February 1, 1995
10.1016/0378-4347(94)00495-q
Cited by 78

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
|PubMed|2002|688